Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391820 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)
A Phase 2 study, sponsored by Alfasigma S.p.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT00391820 is a Phase 2 study that has completed, run by Alfasigma S.p.A.. The registered enrollment target is 360 participants.
The verdict
NCT00391820, a Phase 2 study, has completed, sponsored by Alfasigma S.p.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
Study 0038 compares the safety and effectiveness of an investigational drug, TD-5108 with placebo (a sugar pill) for the treatment of chronic constipation.
Interventions
- DRUG TD-5108
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00391820
The ClinicalTrials.gov registry entry for NCT00391820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alfasigma S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TD-5108 is the first listed.
NCT00391820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00391820 about?
NCT00391820 is a clinical study titled "Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)". Study 0038 compares the safety and effectiveness of an investigational drug, TD-5108 with placebo (a sugar pill) for the treatment of chronic constipation.
What is the current status of trial NCT00391820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2006-10. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00391820?
The interventions under investigation include: TD-5108 (DRUG).
Who is sponsoring clinical trial NCT00391820?
This trial is sponsored by Alfasigma S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.